ATS 2019: Interim analyse van neo adjuvant atezolizumab in resectabel nsclc

June 2019
lcmc3
atezolizumab monotherapie
neo adjuvant atezolizumab
preoperative immune checkpoint inhibitor therapy
Na voorbehandeling met atezolizumab monotherapie wordt uiteindelijk bij 19% het primaire eindpunt gehaald blijkt uit de interim analyse van de lcmc3 studie. Background Small pilot studies (e.g., N Engl J Med. 2018;378:1976) have shown that preoperative immune checkpoint inhibitor therapy may be of benefit in early-stage NSCLC. This large multicenter trial assesses the benefit of neoadjuvant treatment with atezolizumab (atezo; NCT02927301). Methods Patients (pts) w
Wilt u meer lezen? Log dan in.